Jacobi Capital Management’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $583K | Sell |
2,954
-728
| -20% | -$140K | 0.03% | 383 |
|
|
2025
Q4 | $677K | Sell |
3,682
-109
| -3% | -$19.1K | 0.04% | 346 |
|
|
2025
Q3 | $582K | Buy |
3,791
+628
| +20% | +$95K | 0.04% | 364 |
|
|
2025
Q2 | $442K | Sell |
3,163
-1,488
| -32% | -$209K | 0.03% | 410 |
|
|
2025
Q1 | $684K | Sell |
4,651
-379
| -8% | -$54.8K | 0.05% | 307 |
|
|
2024
Q4 | $659K | Buy |
5,030
+13
| +0.3% | +$1.82K | 0.05% | 304 |
|
|
2024
Q3 | $782K | Buy |
5,017
+36
| +0.7% | +$5.81K | 0.06% | 290 |
|
|
2024
Q2 | $777K | Sell |
4,981
-99
| -2% | -$14.9K | 0.07% | 256 |
|
|
2024
Q1 | $688K | Buy |
5,080
+1,430
| +39% | +$189K | 0.06% | 259 |
|
|
2023
Q4 | $492K | Buy |
3,650
+770
| +27% | +$100K | 0.05% | 291 |
|
|
2023
Q3 | $390K | Sell |
2,880
-11
| -0.4% | -$1.5K | 0.04% | 309 |
|
|
2023
Q2 | $414K | Sell |
2,891
-360
| -11% | -$53K | 0.05% | 306 |
|
|
2023
Q1 | $451K | Sell |
3,251
-139
| -4% | -$18.7K | 0.05% | 286 |
|
|
2022
Q4 | $460K | Sell |
3,390
-53
| -2% | -$6.65K | 0.06% | 280 |
|
|
2022
Q3 | $378K | Sell |
3,443
-49
| -1% | -$6.22K | 0.05% | 288 |
|
|
2022
Q2 | $461K | Hold |
3,492
| – | – | 0.06% | 266 |
|
|
2022
Q1 | $463K | Sell |
3,492
-203
| -5% | -$24.3K | 0.06% | 278 |
|
|
2021
Q4 | $430K | Sell |
3,695
-83
| -2% | -$9.77K | 0.05% | 301 |
|
|
2021
Q3 | $454K | Sell |
3,778
-148
| -4% | -$17.2K | 0.06% | 270 |
|
|
2021
Q2 | $470K | Hold |
3,926
| – | – | 0.06% | 247 |
|
|
2021
Q1 | $390K | Buy |
3,926
+388
| +11% | +$39K | 0.06% | 254 |
|
|
2020
Q4 | $354K | Buy |
3,538
+610
| +21% | +$64.6K | 0.06% | 251 |
|
|
2020
Q3 | $321K | Sell |
2,928
-165
| -5% | -$18.4K | 0.06% | 240 |
|
|
2020
Q2 | $327K | Buy |
3,093
+18
| +0.6% | +$1.86K | 0.06% | 238 |
|
|
2020
Q1 | $275K | Sell |
3,075
-319
| -9% | -$30K | 0.06% | 225 |
|
|
2019
Q4 | $338K | Hold |
3,394
| – | – | 0.06% | 230 |
|
|
2019
Q3 | $303K | Buy |
3,394
+9
| +0.3% | +$780 | 0.06% | 236 |
|
|
2019
Q2 | $279K | Buy |
3,385
+41
| +1% | +$3.21K | 0.06% | 240 |
|
|
2019
Q1 | $270K | Buy |
3,344
+126
| +4% | +$9.93K | 0.07% | 191 |
|
|
2018
Q4 | $244K | Sell |
3,218
-543
| -14% | -$42.4K | 0.07% | 192 |
|
|
2018
Q3 | $298K | Sell |
3,761
-1,471
| -28% | -$111K | 0.08% | 151 |
|
|
2018
Q2 | $367K | Buy |
5,232
+1,220
| +30% | +$87.8K | 0.11% | 124 |
|
|
2018
Q1 | $278K | Buy |
4,012
+2,874
| +253% | +$199K | 0.08% | 134 |
|
|
2017
Q4 | $81K | Hold |
1,138
| – | – | 0.03% | 294 |
|
|
2017
Q3 | $78K | Buy |
1,138
+785
| +222% | +$49.6K | 0.03% | 277 |
|
|
2017
Q2 | $24K | Buy |
+353
| New | +$23.1K | 0.01% | 417 |
|
Other funds holding AZN
IA
VCM
VAM
Jacobi Capital Management's AZN Position: Q1 2026 in Review
Jacobi Capital Management reduced its AstraZeneca (AZN) stake by 20% in Q1 2026, selling an estimated $140K and leaving 2,954 shares worth $583K. The position accounts for 0.03% of the portfolio, ranked #383.
Jacobi Capital Management first reported a position in AZN in Q2 2017 and has held it in 36 quarters since. The position peaked at $782K in Q3 2024. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Jacobi Capital Management held 2,954 shares of AstraZeneca worth $583K as of Q1 2026.
- Jacobi Capital Management sold 728 AstraZeneca shares in Q1 2026, an estimated $140K.
- AstraZeneca made up 0.03% of Jacobi Capital Management's portfolio in Q1 2026, its #383 holding.
- Jacobi Capital Management first reported a position in AstraZeneca in Q2 2017 and has held it in 36 quarters since.
- Jacobi Capital Management's AstraZeneca position peaked at $782K in Q3 2024.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Jacobi Capital Management's 13F filing for Q1 2026, filed 14 May 2026.